Welcome to our dedicated page for Guardian Pharmacy Services news (Ticker: GRDN), a resource for investors and traders seeking the latest updates and insights on Guardian Pharmacy Services stock.
Guardian Pharmacy Services, Inc. (NYSE: GRDN) is a long-term care pharmacy services company based in Atlanta, Georgia. This news page aggregates company-issued updates and market-facing announcements so readers can follow how Guardian communicates about its operations, growth, and financial performance over time.
In its public news releases, Guardian highlights its role as one of the nation’s leading long-term care pharmacy services companies, partnering with long-term care facilities to deliver medications and technology-enabled services that are designed to improve adherence to drug regimens and support better clinical outcomes. The company frequently reports on revenue trends, resident counts, and Adjusted EBITDA as part of its quarterly financial results and outlook.
Typical news items for GRDN include quarterly earnings releases, guidance updates, and preliminary financial outlooks, such as reiterations of revenue and Adjusted EBITDA guidance and commentary on expected growth trajectories. Guardian also issues announcements about acquisitions and new pharmacy openings, including transactions that expand its presence into new states or strengthen its footprint in existing regions.
Investors and observers can also find capital markets updates in Guardian’s news, such as information about secondary offerings of Class A common stock, shelf registration statements on Form S-3, and lock-up agreements with pre-IPO stockholders. In addition, the company regularly announces participation in healthcare and investor conferences, where it hosts investor meetings and presentations.
By reviewing the GRDN news feed on this page, readers can track Guardian Pharmacy Services’ reported financial results, expansion activities, and other material communications disclosed through press releases and related announcements.
Guardian Pharmacy Services (NYSE: GRDN) reiterated its 2025 guidance and issued initial 2026 outlook ahead of its J.P. Morgan Healthcare Conference presentation on January 14, 2026. The company reaffirmed 2025 revenue guidance of $1.43B–$1.45B and adjusted EBITDA of $104M–$106M. For 2026 Guardian expects revenue of $1.40B–$1.42B after Inflation Reduction Act drug price reductions and WAC cuts, and adjusted EBITDA of $115M–$118M (~11% growth vs. 2025 guidance) with adjusted EBITDA margin above 8%. The company also completed a single-location pharmacy acquisition in Montana to add a new territory.
Guardian Pharmacy Services (NYSE: GRDN) will participate in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 14, 2026. The company’s leadership will host investor meetings that day and deliver a presentation at 4:30 p.m. PT. A live audio webcast will be available at https://investors.guardianpharmacy.com, with a replay posted shortly after the presentation and available for 30 days.
Guardian Pharmacy Services (NYSE: GRDN) reported third quarter 2025 results and raised full-year guidance. Q3 revenue was $377.4M (+20% YoY) and Adjusted EBITDA was $27.3M (vs. $23.0M). Net income was $9.6M vs. a $(105.8)M loss year-ago. Residents served were ~204,000 (+13% YoY). Diluted EPS was $0.15 with Adjusted EPS of $0.25. Cash totaled $36.5M and there was no long-term debt outstanding under the credit facility.
Guardian raised FY2025 guidance to $1.43B–$1.45B revenue and $104M–$106M Adjusted EBITDA (excludes future acquisitions). Operationally, Guardian closed an acquisition in Oregon to enter the Pacific Northwest. A Form S-3 shelf was filed allowing potential issuance/resale of Class A shares.
Guardian Pharmacy Services (NYSE: GRDN) will participate in the Stephens Investment Conference in Nashville, TN on Wednesday, November 19, 2025. The company will host investor meetings and Fred Burke, co-founder and CEO, will appear in a fireside chat at 11:00 a.m. CT (12:00 p.m. ET). A live audio webcast will be available at the company investor site and a replay will be accessible shortly after the event for 90 days.
Guardian Pharmacy Services (NYSE: GRDN) filed a Form S-3 shelf registration on October 14, 2025 to permit the issuance of up to 1,020,000 new Class A shares and the potential resale of up to 4,980,000 outstanding Class A shares by selling stockholders.
Guardian said neither it nor the selling stockholders have immediate plans to sell under the shelf. The filing is not yet effective. Guardian also executed lock-up agreements covering approximately 17,188,059 shares and the automatic conversion of 12,759,054 Class B shares on March 28, 2026, restricting sales through June 30, 2026. As of September 30, 2025, there were 36,253,744 Class A shares outstanding.
Guardian Pharmacy Services (NYSE: GRDN) will report third quarter 2025 financial results on Monday, November 10, 2025 after market close. A conference call to review results is scheduled for 4:30 PM ET on the same day.
Investors can listen via audio webcast at https://investors.guardianpharmacy.com or dial (646) 564-2877 (U.S.) or +1 (800) 549-8228 (international) using conference ID 11965. A replay will be available shortly after the call and remain accessible for approximately 60 days.
Guardian Pharmacy Services (NYSE:GRDN) announced its participation in the upcoming Jefferies Healthcare Services Conference in Nashville, TN, on September 30, 2025. CEO Fred Burke will participate in a fireside chat with Jefferies analyst Brian Tanquilut at 3:35 p.m. CT (4:35 p.m. ET).
The company will host investor meetings during the conference. A live audio webcast will be available on the company's investor relations website, with a replay accessible for 90 days following the event.
Guardian Pharmacy Services (NYSE:GRDN) reported strong Q2 2025 financial results, with revenue increasing 15% year-over-year to $344.3 million. The company's resident count grew 12% to over 195,000, while Adjusted EBITDA reached $25.0 million.
The company expanded its footprint through strategic acquisitions in Wichita, KS and Seattle, WA, launched a new greenfield pharmacy in Naples, FL, and subsequently acquired Managed Healthcare Pharmacy in Oregon. Guardian also completed a non-dilutive secondary offering of 8.625 million shares, enhancing trading liquidity.
Based on strong H1 2025 performance, Guardian raised its full-year guidance, projecting revenue of $1.39-1.41 billion (up from $1.33-1.35 billion) and Adjusted EBITDA of $100.0-102.0 million (up from $97.0-101.0 million).
Guardian Pharmacy Services (NYSE:GRDN) has announced the acquisition of Managed Healthcare Pharmacy, a leading long-term care (LTC) pharmacy in Oregon. The strategic acquisition marks Guardian's first physical presence in Oregon and expands its Pacific Northwest footprint.
Managed Healthcare Pharmacy, established in 1991, operates in Eugene and Medford, serving assisted living facilities, behavioral health communities, and individuals with intellectual and developmental disabilities across Oregon and Washington. The existing leadership and staff will be retained, and the pharmacy will maintain its current name while benefiting from Guardian's centralized corporate support in areas including data analytics, HR, IT, and payor relations.
Guardian Pharmacy Services (NYSE:GRDN) has scheduled its second quarter 2025 financial results announcement for Monday, August 11, 2025, after market close. The company will host a conference call at 4:30 PM ET to discuss the results.
Investors can access the conference call through an audio webcast on the company's investor relations website or by dialing (646) 564-2877 (U.S.) or +1 (800) 549-8228 (international) with conference ID "95006". A replay will be available for approximately 60 days following the call.
FAQ
What is the current stock price of Guardian Pharmacy Services (GRDN)?
What is the market cap of Guardian Pharmacy Services (GRDN)?
